CVRx, Inc. — Biomedical Watch V2

Traitements9programmes

Essais4liés

Publications0liées

SourceDBlocale

Traitements

9

Molécule	Indication / population	Phase	Objectif	Pays	Résultat
BAROSTIM NEO SystemTo assess the long-term safety and efficacy of the BAROSTIM NEO System in trial (NCT01471834) participants.	Hypertension	Non applicable	À vérifier	Canada, Germany, Netherlands	À vérifier
BAROSTIM NEO System and Medical ManagementThe purpose of this clinical investigation (NCT01679132) is to assess the long-term safety and efficacy of the BAROSTIM NEO System in subjects currently participating in the BAROSTIM Hypertension Pivotal Trial (G120137).	Hypertension	Non applicable	À vérifier	United States	À vérifier
BAROSTIM NEO™ SystemThe purpose of this registry (NCT02880631) is to evaluate the effect of BAROSTIM THERAPY with the BAROSTIM NEO System in the commercial setting in subjects recently implanted under the CE-Marked indication for resistant hypertension.	Hypertension	À vérifier	À vérifier	Germany, Netherlands	À vérifier
Barostim SystemThe purpose of BENEFIT-HF is to demonstrate the safety and effectiveness of Baroreflex Activation Therapy (BAT) with the Barostim System in participants with heart failure, defined as NYHA Functional Class II or III, LVEF \< 50% and NT-proBNP \< 5,000 pg/mL despite being treated with Guideline-Directed Medical Therapies (medications and devices). It includes demonstration that treatment with the Barostim System, relative to usual care medical management, reduces the rate of all-cause mortality and Heart Failure Morbidity (Cardiac Transplant, Durable LVAD, or Worsening Heart Failure Events).	Insuffisance cardiaque	Non applicable	À vérifier	United States	À vérifier
Medical ManagementTo assess the long-term safety and efficacy of the BAROSTIM NEO System in trial (NCT01471834) participants.	Hypertension	Non applicable	À vérifier	Canada, Germany, Netherlands	À vérifier
BAROSTIM NEO System and Medical ManagementThe purpose of this clinical investigation (NCT01679132) is to assess the long-term safety and efficacy of the BAROSTIM NEO System in subjects currently participating in the BAROSTIM Hypertension Pivotal Trial (G120137).	Hypertension	Non applicable	À vérifier	United States	À vérifier
BAROSTIM NEO™ SystemThe purpose of this registry (NCT02880631) is to evaluate the effect of BAROSTIM THERAPY with the BAROSTIM NEO System in the commercial setting in subjects recently implanted under the CE-Marked indication for resistant hypertension.	Hypertension	À vérifier	À vérifier	Germany, Netherlands	À vérifier
BAROSTIM NEO SystemTo assess the long-term safety and efficacy of the BAROSTIM NEO System in trial (NCT01471834) participants.	Hypertension	Non applicable	À vérifier	Canada, Germany, Netherlands	À vérifier
Barostim SystemThe purpose of BENEFIT-HF is to demonstrate the safety and effectiveness of Baroreflex Activation Therapy (BAT) with the Barostim System in participants with heart failure, defined as NYHA Functional Class II or III, LVEF \< 50% and NT-proBNP \< 5,000 pg/mL despite being treated with Guideline-Directed Medical Therapies (medications and devices). It includes demonstration that treatment with the Barostim System, relative to usual care medical management, reduces the rate of all-cause mortality and Heart Failure Morbidity (Cardiac Transplant, Durable LVAD, or Worsening Heart Failure Events).	Insuffisance cardiaque	Non applicable	À vérifier	United States	À vérifier

Essais cliniques

4

Molécule	Indication / population	Phase	NCT	Titre	Statut
Barostim System	Insuffisance cardiaque	Non applicable	NCT07232030	BENEFIT-HF — Barostim-Enabled NEurohormonal Intervention For Improving Treatment of Heart Failure	RECRUITING
BAROSTIM NEO System	Hypertension	Non applicable	NCT01471834	Verification of the Efficacy and Safety of the BAROSTIM NEO System in the Treatment of Drug Resistant Hypertension	ACTIVE_NOT_RECRUITING
BAROSTIM NEO™ System	Hypertension	À vérifier	NCT02880631	BAROSTIM THERAPY™ In Resistant Hypertension	RECRUITING
BAROSTIM NEO System and Medical Management	Hypertension	Non applicable	NCT01679132	BAROSTIM NEO Hypertension Pivotal Trial	COMPLETED

Publications

0

Molécule	Indication / population	Titre	Journal	Date
Aucune publication.